Cure My Disease

Don't miss your cure!

 Log in / Sign up

Dialysis filters with bigger pores put to the test for longer life

NCT ID NCT06660277

Disease control Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 24, 2026 · Last updated Sep 25, 2026 · Updated 1 time

Summary

This trial compares two types of dialysis filters in people who receive hemodialysis three or more times a week. One filter has larger pores that remove more waste products from the blood, while the other is the conventional filter used in most clinics. Researchers will track whether the expanded filter lowers the risk of death from any cause and reduces hospital stays for heart or infection problems. Participants keep their regular dialysis schedule and no extra visits are required.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
an expanded hemodialysis filter with larger pores that removes more waste products from the blood
What this could lead to
If expanded dialysis filters work better, they could become the standard filter for people on hemodialysis and help them live longer. The same filters are already approved and used in Canada, so adoption could be straightforward.
What could go wrong
Removing more waste products may not translate into fewer deaths, and the benefit could be too small to detect. Larger pores might also let useful proteins escape, though the trial monitors for that.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 4,800 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2025

Expected to finish

Apr 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

45 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Inclusion requires that all the following are present: 1. One of: 1. Age 60 years or older; or 2. Age 45 to 59 years with a history of diabetes mellitus (Type 1 or Type 2) regardless of current glycemic status; and 2. Receiving any form of dialysis regularly for the previous 90 days; and 3. Currently receiving HD in-centre (main or satellite unit) 3 or more times per week; and 4. A valid provincial or territorial health insurance card number. Exclusion Criteria: Patients are ineligible if they meet any of the following criteria: 1. Not appropriate for this study in the opinion of the treating nephrologist or dialysis nurse practitioner due to any of: 1. Known or anticipated intolerance to the Nipro Elisio HX dialyzer; or 2. Planned to receive HDF; or 3. Planned to receive nocturnal HD; or 4. Anticipated to discontinue in-centre HD in the next 3 months for any reason (examples: palliation, transplantation, home dialysis, recovery of kidney function, death, others); or 5. Anticipated severe non-adherence to the frequency or duration of prescribed dialysis treatment; or 6. An overriding clinical preference for expanded HD (i.e., dialysis with the Elisio HX or other comparable dialyzer, such as Baxter TheranovaTM); or 7. Another medical, psychosocial, or logistical reason; or 2. Enrolled in another clinical trial that explicitly prohibits concurrent participation in other clinical trials or that would substantially interfere with adherence to the DIALEX procedures (note that DIALEX otherwise permits concurrent participation in other trials); or 3. Previously enrolled in this trial; or 4. Declined participation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease requiring chronic dialysis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome end stage renal failure impaired renal function disease kidney disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic kidney disease requiring chronic dialysis Chronic kidney disease requiring hemodialysis End-stage kidney disease (ESKD) Hemodialysis Kidney disease Kidney failure, chronic Pragmatic randomized controlled trial Renal insufficiency, chronic

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • London Health Sciences Centre

    RECRUITING

    London, Ontario, N6A 5W9, Canada

  • Orillia Soldiers' Memorial Hospital

    RECRUITING

    Orillia, Ontario, L3V 3B5, Canada

  • The Ottawa Hospital

    ACTIVE_NOT_RECRUITING

    Ottawa, Ontario, K1H8L6, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.